Detalles de la búsqueda
1.
Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
BMC Med
; 18(1): 298, 2020 11 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33143745
2.
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.
MAbs
; 16(1): 2324801, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38441119
3.
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.
MAbs
; 14(1): 1993522, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34923896
4.
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
AAPS J
; 24(3): 68, 2022 05 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35554731
5.
Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.
J Neuroimmunol
; 370: 577932, 2022 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35853357
6.
A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel.
J Immunol Methods
; 476: 112692, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31678267
7.
T cell epitope mapping of secukinumab and ixekizumab in healthy donors.
MAbs
; 12(1): 1707418, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31924123
8.
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
J Rheumatol
; 47(4): 539-547, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31203228
9.
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
J Neuroimmunol
; 326: 19-27, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30447419
10.
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
Dermatol Ther (Heidelb)
; 8(1): 57-68, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29392570
11.
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
Dermatol Ther (Heidelb)
; 8(2): 327, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29551008
12.
Low Percentage of Signal Regulatory Protein α/ß+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients.
Front Immunol
; 9: 2865, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30568660
13.
Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?
PLoS One
; 12(10): e0186046, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29023507
14.
Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?
Immun Inflamm Dis
; 5(4): 400-415, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28560793
15.
Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.
Front Immunol
; 8: 500, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28529511
16.
Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
MAbs
; 8(3): 536-50, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26817498
17.
A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors.
MAbs
; 8(2): 253-63, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26821574
18.
Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes.
Cell Mol Immunol
; 17(6): 656-658, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31659246
19.
A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.
J Immunol Methods
; 417: 1-9, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25602137
20.
Stability of anti-immunotherapeutic antibodies in frozen human serum samples.
Bioanalysis
; 6(10): 1395-407, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24958123